Company Information
CIN
Status
Date of Incorporation
23 September 1940
State / ROC
Mumbai / ROC Mumbai
Last Balance Sheet
31 March 2023
Last Annual Meeting
27 September 2023
Paid Up Capital
165,910,084
Authorised Capital
294,500,000
Directors
Mangala Ashok Chandavarkar
Director/Designated Partner
about 2 years ago
about 2 years ago
Mohan Chandavarkar Anand
Director/Designated Partner
over 2 years ago
over 2 years ago
Aditi C Bhanot
Director/Designated Partner
over 2 years ago
over 2 years ago
Vijay Nautamlal Bhatt
Director/Designated Partner
over 2 years ago
over 2 years ago
Ameya Ashok Chandavarkar
Director/Designated Partner
over 2 years ago
over 2 years ago
Ashok Anand Chandavarkar
Director/Designated Partner
over 2 years ago
over 2 years ago
Nandan Mohan Chandavarkar
Director/Designated Partner
over 2 years ago
over 2 years ago
Vijay Maniar
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Mahesh Chandru Bijlani
Director/Designated Partner
about 6 years ago
about 6 years ago
Usha Athreya Chandrasekhar
Director/Designated Partner
about 6 years ago
about 6 years ago
Swati Sandesh Mayekar
Director/Designated Partner
about 10 years ago
about 10 years ago
Past Directors
Melarkode Ganesan Parameswaran
Additional Director
over 6 years ago
over 6 years ago
Uday Kumar Gurkar
Additional Director
over 9 years ago
over 9 years ago
Nomita Ramdas Chandavarkar
Whole Time Director
over 11 years ago
over 11 years ago
Vinod Gurudatta Yennemadi
Additional Director
over 13 years ago
over 13 years ago
Rahim Huseinali Muljiani
Director
over 25 years ago
over 25 years ago
Girish Chinubhai Sharedalal
Director
over 37 years ago
over 37 years ago
Satish Ugrankar Shripad
Director
over 48 years ago
over 48 years ago
Patents
The invention discloses an enantiomeric antifungal compounds of Formula (la) and Formula (lb),
wherein each R1 and R2, which may be the same or different, is independently selected from hydrogen or a halogen selected from fluorine, chlorine, bromine or iodine; each R3 and R4, which may be the same or different, ...
Disclosed herein is an in-situ gelling pharmaceutical composition for delivery of minerals, comprising one or more mineral(s), in-situ gelling polymer(s) in the range of 0.01% to 60%; viscosity modifier(s) in the range of 0.01% to 5% w/v and at least one pharmaceutically acceptable excipient, in a controlled-release...
The invention disclosed herein is a nanodispersion formulation for ocular drug delivery comprising poorly water soluble drug(s), mineral oil, surfactant(s), optionally permeation enhancer and other pharmaceutical acceptable excipients, with improved patient compliance, reduced dosing frequency, safety and better the...
The present invention discloses a topical drug delivery system useful in treatment of infections and inflammations on body surfaces of humans and animals.
The present invention discloses racemization of unwanted enantiomer of the compound of formula (I) or its salts by subjecting the enantiomerically enriched chemical mixture to sequential oxidation and reduction reactions. The invention further discloses a process for recovery of enantiomers from racemic mixtures con...
A process for preparation of Flurbiprofen,which comprises alkylation of 2,4 difluronitrobenzene with dimethy1 ethy1 malonate and subsequent reduction with a hydrogenation catalyst to yield amino-diester followed by Gomberg reaction with benzene to obtain Flurbiprofen crude.Flurbiprofen (crude) is purified through so...
The invention disclosed herein is a solid oral pharmaceutical composition comprising telmisartan and its pharmaceutical salts, atleast one water insoluble diluent, atleast one or more basic agents, one or more surfactant alongwith pharmaceutically acceptable excipients wherein the said composition is free of binder....
The invention disclosed herein is a solid oral pharmaceutical composition comprising telmisartan and its pharmaceutical salts; at least one water-insoluble diluent: at least one basic agent; and pharmaceutically acceptable excipients, wherein the said composition is free of surfactant. emulsifier and water soluble d...
The present invention discloses a process for purification of prostaglandins of formula 1 into enantiomerically pure isomer of formula 2 by reverse phase preparative HPLC, and converting said isomer into prostaglandin derivative of formula 3. The prostaglandin derivative in this invention relates to PGF2α analogues
...
Disclosed herein is a novel controlled-release solid oral pharmaceutical composition of Albendazole, comprising a combination of gastroretentive drug delivery system (GRDDS) and an enteric drug delivery system for effective treatment of luminal nematodes and systemic helminthiasis.
Disclosed herein are novel antifungal compounds of Formula 1, containing 1-substituted, 4-(substituted phenoxymethyl)-1,2.3-triazole moieties coupled to a core having triazole ring, (un)substituted phenyl ring and tertiary alcoholic functionality, and pharmaceutically acceptable salts thereof; methods for preparing ...
Disclosed herein is the process of transforming the undesired 15-epimer of prostaglandin derivatives and intermediates thereof to the desired active isomer of formula 1
The present invention discloses a controlled release gastroretentive dosage form of pregabalin comprising pregabalin and optionally methylcobalamin, in a floating swellable matrix system comprising hydrophilic swellable polymers, in-situ gelling agents, superdisintergrant(s) and other pharmaceutically acceptable exc...
Disclosed herein is a novel gastroretentive delivery system of macrolide consisting of a hydrophilic swellable floating matrix system either alone or in combination with a bioadhesive system, which comprises super-disintegrants together with hydrophilic polymers and in-situ gelling agents to improve the gastroretent...
ABSTRACT:
The present invention discloses an improved process for obtaining Flurbiprofen with high purity.
Disclosed herein is a palatable liquid suspension formulation of calcium supplements for oral administration, comprising micronised calcium citrate malate, stabilized vitamin D3, thixotropic gel-forming agent(s), suspending agent(s) and other pharmaceutically acceptable excipients. The invention further relates to a...
Disclosed herewith is a chronotherapeutic, oral floating gastroretentive controlled release dosage form of Atorvastatin or pharmaceutically acceptable salts, esters or derivatives thereof, comprising rate-controlling agents, solubilizers, gas-generating agent(s), superdisintegrants(s) and other pharmaceutically acce...
The invention disclosed herein is a solid oral pharmaceutical composition comprising telmisartan or a salt thereof, hydrochlorothiazide, an acidifier, basic agent(s) and pharmaceutically acceptable excipients in a single unit, wherein the composition does not include binder and surfactant. The invention further disc...
The present invention discloses a novel sustained-release (SR) gastroretentive dosage form of Aciclovir comprising a gastroretentive, pH-independent swellable and mucoadhesive matrix system.
Disclosed herein is a solid oral gastroretentive dosage form of paracetamol comprising a system of hydrophilic swellable floating matrix in combination with a bioadhesive system, wherein said combination of drug delivery system consists of hydrogel(s), superdisintegrant(s), microenvironmental pH modifier(s) and phar...
Disclosed herein is one pot synthesis for preparation of meclizine hydrochloride which comprises sequential bromination of m-xylene to obtain 3-methyl benzyl bromide followed by in situ condensation of bromocompound with 4-chloro benzhydryl piperazine in the presence of acid acceptor to give meclizine base of formul...
The present invention discloses crystalline Polymorphic Form I of compound 5-(3,5-
dimethylphenoxy-) methyl)-2-oxazolidinone, characterized by x-ray diffraction pattern
having peaks at 10.355, 14.285,18.625, 19.030, 20.810 and 22.475± 0.30 degrees 2 theta
angle, and melting point ranging from 122.5°C to 124°C whi...
Disclosed herein is an oral controlled release pharmaceutical formulation comprising water-soluble drug or pharmaceutically acceptable salts thereof, in a hydrophilic matrix system, further comprising pH independent polymers present in an amount of 5% to 90 % w/w in combination with acid insoluble polymer present in...
Disclosed herein is a process for the preparation of a pharmaceutical composition in the form of a tablet comprising two discrete layers wherein the first sustained release layer is prepared by granulation of a therapeutically effective amount of antibiotic preferably Cloxacillin or Dicloxacillin or its pharmaceutic...
The present invention discloses stabilized formulations of Donepezil where the said formulation is stabilized using inorganic stabilizer.
the present invention relates to a smart drug delivery system comprising of a thin rod having a coarse or uneven surface which is coated with the drug composition. The thin rod serves as a delivery system such that when inserted into the cavity /affected area the drug is released as a result of the environment of th...
Oral dosage forms comprising Cefixime Trihydrate and at least one pharmaceutically acceptable excipient(s), wherein more than 60% of the Cefixime particles are smaller than 20μ or 95% of Cefixime particles are above 250μ is disclosed herein.
The present invention discloses an in -situ synthesis of β,β -1,2-Dihydroxy-1,2-cyclobutnrdiacrylic acid -di-γ -lactone (I).Comprising the steps of dimerisation of 5-Methylene-2 (5H)-furanone (II)in aerobic condition & purrifying the same in a suitable solvent(s).2-Deoxy-D-Ribose(III)on glycosiliation and further pr...
Disclosed herein is a pharmaceutical composition comprises a combination of antacid(s) and a raft-forming agent, along with an anti-flatulent(s) and/or local anesthetic(s) and pharmaceutically acceptable excipients, in a floating dosage form such as tablet, capsule, suspension or a powder for suspension.
...
The present invention discloses novel gastroretentive controlled oral dosage form comprising mineral(s) either alone or in combination with vitamins and other nutraceuticals, wherein the delivery of minerals and nutraceutical substances is at the site of absorption in gastrointestinal tract.
The invention disclosed herein is a solid oral pharmaceutical composition comprising telmisartan and its pharmaceutical salts; atleast one water soluble diluent; one or more basic agents; optionally one or more water insoluble diluents alongwith pharmaceutically acceptable excipients wherein the said composition is ...
The present invention relates to a standardised method of bioassay for detecting the effective concentration of granulocyte colony stimulating factor and estimation of ED50 and specific activity of G-CSF using human acute myeloid cell line. The invention also mentions further use of this technique for estimation of ...
The present invention relates to compounds of formula (1), its solvates and pharmaceutically acceptable salts having antifungal activity and its pharmaceutical composition comprising an effective amount of compound of formula (I).
The invention also relates to a process for the preparation of said compounds by cont...
The present invention relates to resolution of (cis,trans) 5,6 -dihydro -4H-4-ethylamino-6-methylthieno[2,3-b] thiopyran-2-sulfonamide-7,7 -dioxide using dibenzoyl-L-tartaric acid monohydrate or di-p-toluoyl-L-tartaric acid monohydrate as a chiral resolving agent in presence of methanol to obtain hemitartarate salt ...
The invention disclosed herein is a novel chronotherapeutic dosage form which consists of controlled release oral pharmaceutical composition comprising poorly acid soluble drug(s) in hydrophilic matrix system, wherein hydrophilic matrix system comprises acid insoluble polymer(s) in combination with pH independent po...
The invention disclosed herein is a solid oral pharmaceutical composition comprising telmisartan and its pharmaceutical salts, atleast one water insoluble diluent, one or more basic agents, one or more surfactant alongwith pharmaceutically acceptable excipients wherein the said composition is free of binder and wate...
The present invention discloses novel composition of ciprofloxacin or its salts in a clear solution dosage form having excellent physical and chemical stability within the pH range of 4.5-7.0, useful for the treatment of otitis externa and otitis media.
The present invention discloses a novel composition comprising co-processed sodium alginate, process for preparation and application of the co-processed sodium alginate, as an inactive ingredient in the pharmaceutical dosage forms.
The invention relates to novel antifungal compounds and its pharmaceutically acceptable salts, having as part of its structure, imidazolyl or benzimidazolyl derivatives. The imidazolyl derivative may be substituted at 2 position from among the group consiting of aroyl, p-chlororoyl, phenyl hydroxy methine or p-chlor...
Disclosed herein is a process for purification of Lornoxicam with increased yield and purity in a simple, easy and cost-effective manner, without the use of toxic and hazardous materials.
Floating, gastroretentive mouth-dispersing granules of calcium carbonate comprising calcium carbonate as active ingredient, a raft-forming agent, superdisintegrant(s), sweetener(s), organic acid(s) and other pharmaceutical!}/ acceptable excipients.
Disclosed herein are novel antifungal compounds of Formula 1, containing fluconazole pharmacophore moieties coupled with other moieties including aryl enones and chalcones and pharmaceutically acceptable salts thereof, methods for preparing these compounds and pharmaceutical preparations containing these novel compo...
The present invention discloses an improved process for preparation of Rupatadine which involves N-alkylation of desloratadine in presence of sodium hydride, a catalytic amount of sodium iodide and a solvent system.
The present invention discloses a process for preparation of Dorzolamide and its hydrochloride salt with high yield and high purity, wherein the reaction starts with 6-methyl thieno[2,3-b]thiopyran 4-one compound having desired chirality at C-6 position and non-chiralality at C-4 position.
Disclosed herein is a process for preparation of Bromhexine Hydrochloride which comprises bromination of o-nitro toluene and subsequent alkylation of o-nitrobenzyl bromide using N-methyl cyclohexylamine to from N-(2-nitrobenzyl)-N-methylcyclohexyl amine; reduction of N-(2-aminobenzyl)-N-methylcyclohexylamine followe...
The present invention relates to stabilized formulation of Fluconazole polymorph III and method of stabilizing the formulation containing Fluconazole polymorph III.
Disclosed herein is a novel in-situ gel forming system for ocular drug delivery comprises a combination of natural polysaccharide having thixotropic behavior, thermoreversible polymer and a vehicle alongwith one or more optional components selected from active pharmaceutical ingredient(s), buffer, preservative with ...
Disclosed herein is an improved process for preparation of Amlodipine free base and acid addition salts thereof in good yield by deprotecting Phthaloyl Amlodipine using total concentration of 25% aqueous monomethyl amine in the reaction mixture and Amlodipine free base thus obtained is treated with suitable acids in...
Process For Preparation Of 2 Amino 3 Benzoyl Phenylacetyl Derivatives And Novel Intermediate Thereof
The present invention discloses process for the preparation of 2-amino-3-benzoyl-phenylacetyl derivatives having general Formula 1 and the intermediates thereof.
Formula I
Wherein
X= -OH, -ONa, -OK, -NH2, NHR2; -OR1,-
Y= H, Br, Cl, F, I, -OH, -NO2, -NH2, and wherein, R1 is selected from C1 to C4 alkyl; R2...
Disclosed herein is a novel and improved process for obtaining Betaxolol base by reacting Betaxolol with sorbic acid to give sorbate salt thereby removing undesired impurities to give substantially pure form of Betaxolol base.
The present invention discloses novel and commercially viable process for racemization of key chemical intermediate of cetirizine and novel intermediates thereof.
Disclosed herein is a novel process of purification of Glimepiride by micronization and leeching with methanol thereby; substantially reducing undesired impurity B to give highly pure form of Glimepiride.
Disclosed herein is an improved process for preparation of Salbutamol Sulphate with high purity and with individual unknown impurity less than 0.1%.
The present invention provides a new and improved process for sterilization of bulk powder of active pharmaceutical ingredients (APIs), such as brinzolamide powder. The process can include the steps of: providing an API, replacing air, specifically oxygen from the API with inert gas by keeping in a controlled atmosp...
The present invention provides a method for synthesizing glycopyrronium base through a mixed anhydride intermediate and preparation of glycopyrronium bromide therefrom. The method of the present invention is a one pot synthesis from alpha-cyclopentylmandelic acid (CPMA) without isolating ester of CPMA. The present i...
The present invention relates to a novel single-step process for preparing optically pure (RR)-Formoterol (Arformoterol) or its pharmaceutically acceptable salts. The method involves resolving racemic Formoterol (RR, SS) using chiral acids in an organic solvent to yield Arformoterol diastereomeric salt crystals with...
The present invention discloses a process for preparing compound of Lifitegrast of Formula (I) or a salt thereof. Briefly, The present invention discloses a process for the preparation of Lifitegrast of Formula I from alkyl (S)-2-(5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3 (methylsulfonyl)phenyl...
Registered Trademarks
[Class : 3] Cosmetic Products, Toiletries, Skincare Preparations, Body Cleaning And Beauty Care Preparations.
[Class : 35] Advertising, Marketing And Promotional Services
[Class : 35] Advertising, Marketing And Promotional Services
View +588 more Brands for Fdc Limited.
Charges
11 October 1979
Syndicate Bank
1 Lak
24 December 1975
Syndicate Bank
2 Lak
23 March 1992
Syndicate Bank
3 Lak
01 September 1977
Syndicate Bank
14 Lak
13 November 1979
The Saraswat Co-operative Bank Limited
5 Lak
01 September 1979
The Sarasawat Co-operative Bank Ltd.
14 Lak
26 April 2010
Hdfc Bank Limited
6 Crore
17 May 1996
The Saraswat Co-operative Bank Limited
13 Lak
08 May 1986
Syndicate Bank
10 Lak
26 April 1983
Syndicate Bank
10 Lak
21 March 1980
Syndicate Bank
6 Lak
14 April 1977
The Saraswat Co-operative Bank Limited
1 Lak
03 January 1976
Syndicate Bank
69 Thousand
09 January 1978
Syndicate Bank
6 Lak
01 January 1973
Syndicate Bank
2 Lak
01 July 1976
Syndicate Bank
2 Lak
12 September 1975
Syndicate Bank
2 Lak
26 April 1983
Syndicate Bank
0
12 September 1975
Syndicate Bank
0
24 December 1975
Syndicate Bank
0
17 May 1996
The Saraswat Co-operative Bank Limited
0
01 January 1973
Syndicate Bank
0
23 March 1992
Syndicate Bank
0
08 May 1986
Syndicate Bank
0
21 March 1980
Syndicate Bank
0
01 September 1979
The Sarasawat Co-operative Bank Ltd.
0
01 July 1976
Syndicate Bank
0
14 April 1977
The Saraswat Co-operative Bank Limited
0
01 September 1977
Syndicate Bank
0
09 January 1978
Syndicate Bank
0
13 November 1979
The Saraswat Co-operative Bank Limited
0
11 October 1979
Syndicate Bank
0
26 April 2010
Hdfc Bank Limited
0
03 January 1976
Syndicate Bank
0
26 April 1983
Syndicate Bank
0
12 September 1975
Syndicate Bank
0
24 December 1975
Syndicate Bank
0
17 May 1996
The Saraswat Co-operative Bank Limited
0
01 January 1973
Syndicate Bank
0
23 March 1992
Syndicate Bank
0
08 May 1986
Syndicate Bank
0
21 March 1980
Syndicate Bank
0
01 September 1979
The Sarasawat Co-operative Bank Ltd.
0
01 July 1976
Syndicate Bank
0
14 April 1977
The Saraswat Co-operative Bank Limited
0
01 September 1977
Syndicate Bank
0
09 January 1978
Syndicate Bank
0
13 November 1979
The Saraswat Co-operative Bank Limited
0
11 October 1979
Syndicate Bank
0
26 April 2010
Hdfc Bank Limited
0
03 January 1976
Syndicate Bank
0
Documents
Form Addendum to AOC-4 CSR-05032024_signed
SHAREHOLDERDETAILS_F76969435_FDCINDIA19_20231129103132.xlsx
Form AOC-4(XBRL)-15112023_signed
Form MGT-7-08112023_signed
Form MSME FORM I-31102023
Optional Attachment-(1)-01112023
Copy of MGT-8-01112023
List of share holders, debenture holders;-01112023
Optional Attachment-(2)-01112023
Statement of subsidiaries as per section 129-Form AOC-1 (To be attached in respect of Foreign subsidiaries)-25102023
Optional Attachment-(1)-25102023
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-25102023
XBRL document in respect Consolidated financial statement-25102023
Optional Attachment-(2)-25102023
Form AOC-4(XBRL)-25102023
Form MSME FORM I-24102023_signed
Form MGT-15-05102023_signed
Optional Attachment-(1)-05102023
Form MGT-7-24092023_signed
Form Addendum to AOC-4 CSR-30032023
Form MGT-6-21122022_signed
-20122022
Optional Attachment-(1)-20122022
Optional Attachment-(1)-18112022
Optional Attachment-(2)-18112022
Copy of MGT-8-18112022
MGT_7_FDC_F45238193_SANJAYRD65_20221118165731.xlsm
Form MGT-7-18112022
Form MSME FORM I-29102022
Form MSME FORM I-29102022
